Avertissement: Ce site agrège des données publiques officielles provenant de la FDA, ClinicalTrials.gov, PubMed et SEC EDGAR à titre de référence générale uniquement. Il ne constitue pas un avis médical, un diagnostic, une recommandation de traitement ni un conseil en investissement.

PubMed

Communicating Healthcare Economic and Pre-approval Information With Healthcare Decision-Makers: Opportunities Following the 21st Century Cures Act and FDA Guidance.

PMID : 30488029 ·

A, l, e, x, a, n, d, e, r, , N, i, y, a, z, o, v, ;, , D, e, n, i, s, e, , L, e, n, c, i

RevueFrontiers in public health
Année
PMID30488029

Résumé

With rising US healthcare costs, population health decision-makers have expressed interest in receiving pre-approval information to help with the budgeting and forecasting needed to accommodate pharmaceutical and medical device launches. Additionally, there has been a strong emphasis placed on the economics and quality of new products. Manufacturers have historically been reluctant to share pre-approval or healthcare economic information (HCEI) due to unclear regulatory guidance for these types

Source officielle

Voir sur PubMed →

Données issues de PubMed / NCBI. Pour le texte intégral et les informations les plus récentes, consultez toujours la notice officielle.

↑